Hunter Perkins Capital Management LLC Buys Shares of 9,370 Omnicell, Inc. $OMCL

Hunter Perkins Capital Management LLC purchased a new stake in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 9,370 shares of the company's stock, valued at approximately $275,000.

Several other large investors have also recently made changes to their positions in OMCL. GAMMA Investing LLC increased its holdings in Omnicell by 37.1% in the 2nd quarter. GAMMA Investing LLC now owns 1,694 shares of the company's stock valued at $50,000 after purchasing an additional 458 shares during the last quarter. AlphaQuest LLC grew its stake in shares of Omnicell by 79.0% in the first quarter. AlphaQuest LLC now owns 6,400 shares of the company's stock valued at $224,000 after buying an additional 2,824 shares in the last quarter. New Age Alpha Advisors LLC purchased a new stake in shares of Omnicell in the 1st quarter valued at $233,000. EntryPoint Capital LLC lifted its stake in Omnicell by 21.6% during the 1st quarter. EntryPoint Capital LLC now owns 6,671 shares of the company's stock worth $233,000 after acquiring an additional 1,184 shares in the last quarter. Finally, EP Wealth Advisors LLC purchased a new position in Omnicell during the 1st quarter valued at about $245,000. 97.70% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Omnicell news, EVP Corey J. Manley sold 3,880 shares of the business's stock in a transaction on Friday, September 12th. The shares were sold at an average price of $33.25, for a total value of $129,010.00. Following the transaction, the executive vice president directly owned 110,653 shares of the company's stock, valued at approximately $3,679,212.25. The trade was a 3.39% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 2.52% of the stock is currently owned by company insiders.

Omnicell Stock Performance

NASDAQ OMCL opened at $30.95 on Monday. The firm has a market cap of $1.42 billion, a P/E ratio of 61.90, a P/E/G ratio of 6.76 and a beta of 0.88. Omnicell, Inc. has a 52-week low of $22.66 and a 52-week high of $55.74. The business's 50-day moving average price is $31.51 and its 200 day moving average price is $30.54. The company has a quick ratio of 1.24, a current ratio of 1.42 and a debt-to-equity ratio of 0.13.

Omnicell (NASDAQ:OMCL - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The company reported $0.45 earnings per share for the quarter, topping analysts' consensus estimates of $0.30 by $0.15. Omnicell had a return on equity of 4.27% and a net margin of 2.01%.The company had revenue of $290.56 million during the quarter, compared to analysts' expectations of $275.57 million. During the same period last year, the firm earned $0.51 EPS. The firm's revenue for the quarter was up 5.0% on a year-over-year basis. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS. On average, equities research analysts expect that Omnicell, Inc. will post 1.09 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have issued reports on OMCL shares. Wall Street Zen lowered shares of Omnicell from a "strong-buy" rating to a "buy" rating in a research note on Saturday, August 9th. Piper Sandler cut their target price on shares of Omnicell from $57.00 to $55.00 and set an "overweight" rating on the stock in a research note on Monday, August 11th. Weiss Ratings reissued a "sell (d+)" rating on shares of Omnicell in a research report on Saturday, September 27th. Finally, Wells Fargo & Company upped their price objective on Omnicell from $37.00 to $40.00 and gave the stock an "overweight" rating in a research report on Monday, July 21st. Four equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company has an average rating of "Hold" and a consensus price target of $46.71.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.

Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.